Thyroid Gland Oncocytic Follicular Carcinoma clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may stimulate the immune system to attack the cancer, and kinase inhibitors, such as lenvatinib, may interfere with the ability of tumor cells to grow and spread.
at UCSD UCLA